These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

232 related articles for article (PubMed ID: 34690963)

  • 1. Mechanism of Action, Resistance, Synergism, and Clinical Implications of Delamanid Against Multidrug-Resistant
    Khoshnood S; Taki E; Sadeghifard N; Kaviar VH; Haddadi MH; Farshadzadeh Z; Kouhsari E; Goudarzi M; Heidary M
    Front Microbiol; 2021; 12():717045. PubMed ID: 34690963
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Activities and Secretion of Cytokines Caused by Delamanid on Macrophages Infected by Multidrug-Resistant
    Lyu XL; Lin TT; Gao JT; Jia HY; Zhu CZ; Li ZH; Dong J; Sun Q; Shu W; Pan LP; Zhang ZD; Li Q
    Front Immunol; 2021; 12():796677. PubMed ID: 35003120
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Spontaneous Mutational Patterns and Novel Mutations for Delamanid Resistance in Mycobacterium tuberculosis.
    Liu Y; Shi J; Li L; Wu T; Chu P; Pang Y; Guo Y; Gao M; Lu J
    Antimicrob Agents Chemother; 2022 Dec; 66(12):e0053122. PubMed ID: 36448833
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Delamanid: From discovery to its use for pulmonary multidrug-resistant tuberculosis (MDR-TB).
    Liu Y; Matsumoto M; Ishida H; Ohguro K; Yoshitake M; Gupta R; Geiter L; Hafkin J
    Tuberculosis (Edinb); 2018 Jul; 111():20-30. PubMed ID: 30029909
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Delamanid when other anti-tuberculosis-treatment regimens failed due to resistance or tolerability.
    Kwon YS; Jeong BH; Koh WJ
    Expert Opin Pharmacother; 2015 Feb; 16(2):253-61. PubMed ID: 25327169
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Delamanid Central Nervous System Pharmacokinetics in Tuberculous Meningitis in Rabbits and Humans.
    Tucker EW; Pieterse L; Zimmerman MD; Udwadia ZF; Peloquin CA; Gler MT; Ganatra S; Tornheim JA; Chawla P; Caoili JC; Ritchie B; Jain SK; Dartois V; Dooley KE
    Antimicrob Agents Chemother; 2019 Oct; 63(10):. PubMed ID: 31383662
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Adduct Formation of Delamanid with NAD in Mycobacteria.
    Hayashi M; Nishiyama A; Kitamoto R; Tateishi Y; Osada-Oka M; Nishiuchi Y; Kaboso SA; Chen X; Fujiwara M; Inoue Y; Kawano Y; Kawasaki M; Abe T; Sato T; Kaneko K; Itoh K; Matsumoto S; Matsumoto M
    Antimicrob Agents Chemother; 2020 Apr; 64(5):. PubMed ID: 32152081
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Molecular characterization of multidrug-resistant tuberculosis against levofloxacin, moxifloxacin, bedaquiline, linezolid, clofazimine, and delamanid in southwest of China.
    Zheng H; He W; Jiao W; Xia H; Sun L; Wang S; Xiao J; Ou X; Zhao Y; Shen A
    BMC Infect Dis; 2021 Apr; 21(1):330. PubMed ID: 33832459
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Delamanid for the treatment of pulmonary multidrug-resistant tuberculosis.
    Thakare R; Soni I; Dasgupta A; Chopra S
    Drugs Today (Barc); 2015 Feb; 51(2):117-23. PubMed ID: 25756067
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prevalence of Mycobacterium tuberculosis resistant to bedaquiline and delamanid in China.
    He W; Liu C; Liu D; Ma A; Song Y; He P; Bao J; Li Y; Zhao B; Fan J; Cheng Q; Zhao Y
    J Glob Antimicrob Resist; 2021 Sep; 26():241-248. PubMed ID: 34214699
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Whole Genome Sequencing for the Analysis of Drug Resistant Strains of
    Nieto Ramirez LM; Quintero Vargas K; Diaz G
    Antibiotics (Basel); 2020 Mar; 9(3):. PubMed ID: 32209979
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Delamanid expanded access novel treatment of drug resistant tuberculosis.
    Rustomjee R; Zumla A
    Infect Drug Resist; 2015; 8():359-66. PubMed ID: 26604805
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Delamanid suppresses CXCL10 expression
    Qiao M; Li S; Yuan J; Ren W; Shang Y; Wang W; Liu R; Zhang F; Li Q; Wu X; Lu J; Gao M; Pang Y
    Front Immunol; 2022; 13():923492. PubMed ID: 36426362
    [TBL] [Abstract][Full Text] [Related]  

  • 14. An Experience with Delamanid in an XDR TB Case - Case Report.
    Mohan N; Kaur M; Singhal L; Saini V; Chander J
    Infect Disord Drug Targets; 2021; 21(4):637-639. PubMed ID: 32691718
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prevalence and molecular characterizations of seven additional drug resistance among multidrug-resistant tuberculosis in China: A subsequent study of a national survey.
    Wang G; Jiang G; Jing W; Zong Z; Yu X; Chen S; Li W; Huang H
    J Infect; 2021 Mar; 82(3):371-377. PubMed ID: 33556430
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Genetic diversity of candidate loci linked to Mycobacterium tuberculosis resistance to bedaquiline, delamanid and pretomanid.
    Gómez-González PJ; Perdigao J; Gomes P; Puyen ZM; Santos-Lazaro D; Napier G; Hibberd ML; Viveiros M; Portugal I; Campino S; Phelan JE; Clark TG
    Sci Rep; 2021 Sep; 11(1):19431. PubMed ID: 34593898
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Additional Drug Resistance in Patients with Multidrug-resistant Tuberculosis in Korea: a Multicenter Study from 2010 to 2019.
    Lee T; Lee SJ; Jeon D; Lee HY; Kim HJ; Kang BH; Mok J
    J Korean Med Sci; 2021 Jul; 36(26):e174. PubMed ID: 34227261
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Delamanid, linezolid, levofloxacin, and pyrazinamide for the treatment of patients with fluoroquinolone-sensitive multidrug-resistant tuberculosis (Treatment Shortening of MDR-TB Using Existing and New Drugs, MDR-END): study protocol for a phase II/III, multicenter, randomized, open-label clinical trial.
    Lee M; Mok J; Kim DK; Shim TS; Koh WJ; Jeon D; Lee T; Lee SH; Kim JS; Park JS; Lee JY; Kim SY; Lee JH; Jo KW; Jhun BW; Kang YA; Ahn JH; Kim CK; Shin S; Song T; Shin SJ; Kim YR; Ahn H; Hahn S; Won HJ; Jang JY; Cho SN; Yim JJ
    Trials; 2019 Jan; 20(1):57. PubMed ID: 30651149
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Delamanid: first global approval.
    Ryan NJ; Lo JH
    Drugs; 2014 Jun; 74(9):1041-5. PubMed ID: 24923253
    [TBL] [Abstract][Full Text] [Related]  

  • 20. OPC-67683, a nitro-dihydro-imidazooxazole derivative with promising action against tuberculosis in vitro and in mice.
    Matsumoto M; Hashizume H; Tomishige T; Kawasaki M; Tsubouchi H; Sasaki H; Shimokawa Y; Komatsu M
    PLoS Med; 2006 Nov; 3(11):e466. PubMed ID: 17132069
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.